Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nrf2 sirna
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical, Intracerebral, In Vitro Transfection
01
Overview
nrf2 sirna is a synthetic or bioengineered small interfering RNA (siRNA) designed to specifically target and silence the expression of the transcription factor Nuclear factor (erythroid-derived 2)-like 2 (NRF2)[1]. NRF2 is a master regulator of cellular antioxidant responses, and its overexpression is implicated in resistance to chemotherapy and poor prognosis in certain cancers, such as osteosarcoma[1]. The mechanism of action of nrf2 sirna involves entering the cell, being processed by the RNA-induced silencing complex (RISC), and directing the degradation of NRF2 mRNA, leading to reduced NRF2 protein expression. This results in downregulation of NRF2-regulated antioxidant enzymes (e.g., heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1), increased intracellular reactive oxygen species (ROS), and enhanced sensitivity to chemotherapeutic agents like doxorubicin, cisplatin, and sorafenib in cancer cells[1]. Currently, nrf2 sirna is primarily used as a research tool in preclinical studies and is not an approved therapeutic agent[1].
- Other names
- nrf2 knockdown small interfering RNAnrf-2 knockdown small interfering RNAnrf 2 knockdown small interfering RNAsiRNA targeting NRF2
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on nrf2 sirna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nrf2 sirna.